fda ruling semaglutide FBI issues safety warning about counterfeit versions of weight loss drug US judge upholds FDA's removal

Its triple-pathway profile makes it a standout in research focused on appetite signaling, energy balance, glucose regulation, and metabolic adaptation

You are eating in a compressed window, energy dips mid-afternoon, and traditional Iftar spreads are calorie-dense

6, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive results from a Phase 2 trial evaluating the safety and efficacy of eloralintide, an investigational once-weekly, selective amylin receptor agonist, in 263 adults with obesity or overweight with at least one obesity-related comorbidity and without type 2 diabetes

The effect of levocarnitine for plasmatic matrix metalloproteinases (MMPS) on acute cerebral infarct patients